Search and analyze individual stocks with comprehensive metrics
Aspira Pathlab
Fundamental Score
Aspira Pathlab Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ASPIRA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (33.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.37%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (16.44%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 24.56 vs Industry: 40.71)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (2450.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Consistent Growth Track Record (21.18% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (19.60% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (20.07% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Interest Coverage (8.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Elevated Debt Levels (D/E: 1.12)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Low Promoter Commitment (18.39%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Healthcare Service Provider sector...
Financial Statements
Comprehensive financial data for Aspira Pathlab
About ASPIRA
Company Details
Market Information
Performance
ASPIRA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of ASPIRA?
ASPIRA is currently trading at ₹65.14 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of ASPIRA shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of ASPIRA and what does it mean?
ASPIRA has a P/E ratio of 24.56x compared to the industry average of 40.71x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹25 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is ASPIRA performing according to Bull Run's analysis?
ASPIRA has a Bull Run fundamental score of 58/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 33.63%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does ASPIRA belong to?
ASPIRA operates in the Healthcare Services industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Aspira Pathlab. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for ASPIRA?
ASPIRA has an ROE of 33.63%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Aspira Pathlab generates profits from shareholders' equity. An ROE of 34% means the company generates ₹34 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is ASPIRA's debt-to-equity ratio and what does it indicate?
ASPIRA has a debt-to-equity ratio of 1.12, which indicates high leverage that increases financial risk. This means the company has ₹112 of debt for every ₹100 of equity. Higher leverage can amplify returns during good times but increases bankruptcy risk during downturns.
What is ASPIRA's dividend yield and is it a good dividend stock?
ASPIRA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has ASPIRA grown over the past 5 years?
ASPIRA has achieved 5-year growth rates of: Sales Growth 21.18%, Profit Growth 20.07%, and EPS Growth 19.60%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in ASPIRA and why does it matter?
Promoters hold 18.39% of ASPIRA shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does ASPIRA compare with its industry peers?
ASPIRA trades at P/E 24.56x vs industry average 40.71x, with ROE of 33.63% and ROCE of 17.37%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether ASPIRA is outperforming its competitive set in profitability, growth, and valuation metrics.
What is ASPIRA's market capitalization and what category does it fall into?
ASPIRA has a market capitalization of ₹63 crores, making it a Mid-cap stock. Mid-cap stocks balance growth potential with moderate risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for ASPIRA?
Key ratios for ASPIRA: ROE 33.63% (Excellent), ROCE 17.37%, P/E 24.56x, Debt-to-Equity 1.12, Interest Coverage 8.26x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is ASPIRA stock and what is its beta?
ASPIRA has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for ASPIRA?
ASPIRA has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹65.14, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in ASPIRA?
Key risks for ASPIRA include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 1.12), and operational challenges. The stock has a Fundamental Score of 58/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Healthcare Services include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is ASPIRA's operating profit margin and how has it trended?
ASPIRA has a 5-year average Operating Profit Margin (OPM) of 16.44%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is ASPIRA's quarterly performance in terms of sales and profit growth?
ASPIRA's recent quarterly performance shows YoY Sales Growth of 13.15% and YoY Profit Growth of 2450.00%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in ASPIRA?
ASPIRA has FII holding of 0.00% and DII holding of 0.00%, totaling 0.00% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.